Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serodus, a biopharmaceutical company engaged in the development of compounds for cardiovascular diseases, has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367).
Subscribe to our email newsletter
Serodus has in-licensed RO1160367, a drug candidate ready to enter a clinical Phase II Proof-of-Concept study in heart failure.
Under the Agreement, Serodus will receive the full preclinical and clinical documentation for RO1160637 and in return, Roche will receive an upfront payment as well as be entitled to receive development, regulatory and commercial milestone payments.
Additionally, Roche is eligible to receive royalties on sales of products commercialised under the license.
Serodus has been granted the exclusive development, manufacturing and worldwide marketing and sale rights with the rights to sub-license.
In certain cases, Roche has a right to negotiate to regain the product rights.
Serodus CEO Eva Steiness said that they are excited about this opportunity to work with Roche compound.
"This agreement will enable Serodus to move its heart failure programme directly into the clinic without waiting for our own preclinical development," Steiness said.